|
ZNF383 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.64213087572307E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.69098068880658E-12 |
| Normal-vs-Stage2 |
2.51387799465874E-12 |
| Normal-vs-Stage3 |
3.33066907387547E-15 |
| Normal-vs-Stage4 |
4.44089209850063E-16 |
| Stage1-vs-Stage2 |
8.679800E-01 |
| Stage1-vs-Stage3 |
1.344450E-01 |
| Stage1-vs-Stage4 |
1.621690E-02 |
| Stage2-vs-Stage3 |
2.503000E-01 |
| Stage2-vs-Stage4 |
5.179600E-02 |
| Stage3-vs-Stage4 |
3.988200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.63002944475465E-12 |
| Normal-vs-AfricanAmerican |
1.09449999952105E-07 |
| Normal-vs-Asian |
8.71913652389367E-12 |
| Caucasian-vs-AfricanAmerican |
3.831200E-01 |
| Caucasian-vs-Asian |
1.636440E-01 |
| AfricanAmerican-vs-Asian |
8.887400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.67632574488152E-12 |
| Normal-vs-Female |
1.25455201782643E-14 |
| Male-vs-Female |
6.605000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.64153152077051E-14 |
| Normal-vs-Age(41-60Yrs) |
1.62092561595273E-14 |
| Normal-vs-Age(61-80Yrs) |
1.0769163338864E-14 |
| Normal-vs-Age(81-100Yrs) |
1.544310E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.308000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.017400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.476400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.164800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.993400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.435000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.43629999999717E-05 |
| Classical-VS-Follicular |
6.322400E-01 |
| Classical-VS-Other |
3.168200E-01 |
| Classical-VS-Normal |
2.37210251441411E-12 |
| Tall-VS-Follicular |
9.416600E-04 |
| Tall-VS-Other |
3.845800E-01 |
| Tall-VS-Normal |
1.11022302462516E-16 |
| Follicular-VS-Other |
4.312000E-01 |
| Follicular-VS-Normal |
8.17901302241353E-13 |
| Other-VS-Normal |
1.248500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.64590563400679E-12 |
| Normal-vs-N1 |
1.63424829224823E-12 |
| N0-vs-N1 |
2.494400E-01 |
|
|
